B7-H3 in Solid Tumors: Expression, Treatment Outcomes & Survival

Are you familiar with B7-H3 and its role in the body? Challenge your skills and boost your confidence by exploring this emerging anti-cancer drug therapy target. Receive real-time feedback and curated resources based on your current level of knowledge.

Your customized educational pathway, available for download upon activity completion, will feature education developed in collaboration with expert faculty on the B7 family, the effects of B7-H3 on immune pathways, the rationale for B7-H3 as a drug target, and a review of B7-H3 targeted agents currently under development.

• Assess the role of B7-H3 in normal and tumor tissues and its potential as a novel target for anti-cancer therapies
• Differentiate between the various mechanisms of action associated with emerging B7-H3 checkpoint inhibitors for multiple cancers, including SCLC, esophageal and prostate cancers, and NSCLC squamous cell

• 0.5 CME/CE for Physicians (ACCME)
• 0.5 CME/CE for Physician Assistants (AAPA)
• 0.5 CH/CE for Nurse Practitioners (AANP)
• 0.5 CPE for Pharmacists (ACPE + NABP)
• 0.5 CNE for Nurses (ANCC)

This activity is provided by PRIME Education. There is no fee to participate. This activity is supported by an educational grant from Daiichi Sankyo, Inc.